Results From a Phase 3 Study of Voxzogo (Vosoritide) in Children With Hypochondroplasia

The Importance of Early Diagnosis in IgA Nephropathy

Colors of SM: Expressions of Life with Systemic Mastocytosis

CEPHEUS Clinical Trial of Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma

Medical Treatment and Stem-Cell Transplantation in Patients With Cutaneous T-Cell Lymphoma by CheckRare Staff| Published on: Jun 17, 2026

Medical Treatment and Stem-Cell Transplantation in Patients With Cutaneous T-Cell Lymphoma by CheckRare Staff| Published on: Jun 17, 2026 Lauren Shea, MD, Assistant Professor of Hematology and Oncology, University of Alabama, Birmingham, discusses important aspects of medical treatment and stem-cell transplantation in patients with cutaneous T-cell lymphoma (CTCL). https://checkrare.com/medical-treatment-and-stem-cell-transplantation-in-patients-with-cutaneous-t-cell-lymphoma/

Antibody therapy points to a new treatment era for primary membranous nephropathy Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/antibody-therapy-points-to-a-new-treatment-era-for-primary-membranous-nephropathy-17262 Primary membranous nephropathy (pMN) is a kidney-specific autoimmune disease characterized by heavy proteinuria and immune-mediated injury to the glomeruli, the kidney’s microscopic filters. It is a leading cause of nephrotic syndrome in nondiabetic adults worldwide, accounting for 20-37 percent of cases in most reports and up to 40 percent in adults over 60

Cell and gene therapy's next challenge is not the science, it's everything else Written byAndrea Corona

Cell and gene therapy's next challenge is not the science, it's everything else The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do. Written byAndrea Corona https://www.drugdiscoverynews.com/cell-and-gene-therapy-s-next-challenge-is-not-the-science-it-s-everything-else-17261 Cell and gene therapy (CGT) has arrived. The question a panel at the Convention on Pharmaceutical Ingredients (CPHI) Americas 2026 in Philadelphia spent an hour working through was not whether these modalities work — it was whether the industry surrounding them is built for what comes next.